TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30745343

Group type: EXPERIMENTAL
Intervention: Audiovisual learning aid (Calibrated Periodontal Training Video)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (only probing technique instruction from prior lectures)
Number of subjects: 22
Study: 28241357

Group type: EXPERIMENTAL
Intervention: Collaborative care (n=344)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Usual care (n=361)
Number of subjects: 705
Study: 25083727

Group type: EXPERIMENTAL
Intervention: Repeated-sprint training in hypoxia (RSH, 3000 m; FiO2, 13.8%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Repeated-sprint training in normoxia (RSN, 300 m; FiO2, 20.9%)
Number of subjects: 17
Study: 23998910

Group type: EXPERIMENTAL
Intervention: Isoflavone intake (highest quartile Q4: 1.6‐78.8 mg/d)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Isoflavone intake (Q4)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Isoflavone intake
Number of subjects: 259
Study: 22133962

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash (experimental group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo mouthwash (control group)
Number of subjects: 33
Study: 19734392

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Self-diagnosed depressed women
Number of subjects: 506

Group type: COMPARATOR
Intervention: Nondepressed women
Number of subjects: 506
Study: 16269419

Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 17073

Group type: EXPERIMENTAL
Intervention: RBBB with anterior AMI
Number of subjects: 17073

Group type: EXPERIMENTAL
Intervention: RBBB with inferior AMI
Number of subjects: 17073

Group type: EXPERIMENTAL
Intervention: New LBBB
Number of subjects: 17073

Group type: EXPERIMENTAL
Intervention: New RBBB with anterior AMI
Number of subjects: 17073

Group type: EXPERIMENTAL
Intervention: New RBBB with inferior AMI
Number of subjects: 17073
Study: 15281334

Group type: EXPERIMENTAL
Intervention: ED-based intervention to link low-income urban children with asthma to their primary care providers
Number of subjects: 527
Study: 11038995

Group type: EXPERIMENTAL
Intervention: Xuan Fei Ding Chuan Wan and Xiao Chuan Gu Ben Wan
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 9052630

Group type: EXPERIMENTAL
Intervention: Initial clinical presentation features
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Corneal infiltrate, cataract wound abnormalities, afferent pupillary defect, loss of red reflex, initial light perception‐only vision, symptom onset within 2 days of surgery
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Visualized retinal vessel
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Eye pain
Number of subjects: 420
Study: 8159835

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin 1 g IV before surgical incision and then 8-hourly x 3 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: cefuroxime 2 g IV before surgical incision and then 8-hourly x 3 days
Number of subjects: 200
Study: 6461677

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30376079

Group type: EXPERIMENTAL
Intervention: Lumicitabine (ALS‐008176 or JNJ‐64041575)
Number of subjects: 0
Study: 28729019

Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-10
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30
Number of subjects: 575

Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 575

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 575
Study: 26263244

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23823005

Group type: EXPERIMENTAL
Intervention: PICC insertion
Number of subjects: 49
Study: 22913642

Group type: EXPERIMENTAL
Intervention: Educative intervention involving peer-visit from a trained GP to motivate patient-centred communication techniques and decision aids.
Number of subjects: 780

Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Educative intervention (I).
Number of subjects: 780
Study: 19896624

Group type: EXPERIMENTAL
Intervention: Independent training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Proctored training
Number of subjects: 36
Study: 17922355

Group type: EXPERIMENTAL
Intervention: Instructive case-based exams
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Case discussions and question-answer sessions
Number of subjects: 382
Study: 17198589

Group type: EXPERIMENTAL
Intervention: FES group (n = 13), receiving standard rehabilitation combined with FES 30 minutes per day, 5 days per week for 3 weeks.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FES group (n = 13)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group (n = 15)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 46
Study: 12595509

Group type: EXPERIMENTAL
Intervention: Low AGE diet for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: High AGE diet for 4 weeks
Number of subjects: 26
Study: 10528958

Group type: EXPERIMENTAL
Intervention: Hospital Information System (HIS) implemented in 24 district hospitals (early implementation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hospital Information System (HIS) not implemented in 24 district hospitals (late implementation)
Number of subjects: 42
Study: 7497556

Group type: EXPERIMENTAL
Intervention: Conventional surgical tracheostomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Percutaneous dilational tracheostomy
Number of subjects: 53
Study: 1683196

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (600 micrograms daily divided into three doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (identical appearance and taste)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 72
Study: 6749826

Group type: EXPERIMENTAL
Intervention: Amitriptyline-perphenazine (100/8-150/12 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Doxepin (100-150 mg/day)
Number of subjects: 130
Study: 30642441

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 425

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 425
Study: 29075343

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL over seven days followed by 10 mL until day 30)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25359354

Group type: EXPERIMENTAL
Intervention: Immediate isoniazid treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deferred isoniazid treatment
Number of subjects: 60
Study: 23075453

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) at a standardised pressure of 30 N
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cricoid pressure (CP)
Number of subjects: 50
Study: 21742465

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 2344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2344
Study: 18777410

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Exemestane
Number of subjects: 80
Study: 17072689

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol/remifentanil/rocuronium (TIVA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhalational opioid‐free anesthesia with sevoflurane/rocuronium (GAS)
Number of subjects: 50
Study: 12934722

Group type: EXPERIMENTAL
Intervention: Intervention group (safety audit and safety behavior training)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 990
Study: 10618560

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (goal dose 100 microgram/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 100
Study: 8939149

Group type: EXPERIMENTAL
Intervention: 600 mg zileuton
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: 400 mg zileuton
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 1393176

Group type: EXPERIMENTAL
Intervention: Directed multisensory stimulation (SDS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-directed stimulation (NDS)
Number of subjects: 6
Study: 3919401

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29878939

Group type: EXPERIMENTAL
Intervention: Personalized fluid therapy using noninvasive cardiac output (Clearsight system) monitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Protocolized fluid therapy approach
Number of subjects: 40
Study: 29246348

Group type: EXPERIMENTAL
Intervention: 15‐item preconception health screening and counseling and 90‐day multivitamin supply
Number of subjects: 415

Group type: COMPARATOR
Intervention: Preconception health and community resource handouts and 90‐day multivitamin supply
Number of subjects: 415
Study: 27052531

Group type: EXPERIMENTAL
Intervention: Folic Acid 400 μg/d
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Folic Acid 800 μg/d
Number of subjects: 605

Group type: COMPARATOR
Intervention: Creatine 3 g/d
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Creatine plus Folic Acid 400 μg/d
Number of subjects: 605
Study: 24314907

Group type: COMPARATOR
Intervention: Schizophrenia patients (SZ)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Bipolar disorder type I patients (BP)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Small SZ subgroup not receiving antipsychotic medication (n=10)
Number of subjects: 73
Study: 22425936

Group type: EXPERIMENTAL
Intervention: Treatment group (TTM tailored interventions)
Number of subjects: 9461

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9461
Study: 20061906

Group type: EXPERIMENTAL
Intervention: 30 mg monthly intramuscular octreotide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17283005

Group type: EXPERIMENTAL
Intervention: Trendelenburg position with hip flexion (hip flexion group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trendelenburg position without hip flexion (control group)
Number of subjects: 40
Study: 16109001

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral school-based universal primary prevention program
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study: 11535320

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine administered by needle-free jet injector (JI)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine administered by one JI device
Number of subjects: 304

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine administered by needle and syringe (N&S)
Number of subjects: 304
Study: 9716243

Group type: EXPERIMENTAL
Intervention: Propentofylline (300 mg t.i.d. taken 1 h before meals)
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1260
Study: 8142094

Group type: EXPERIMENTAL
Intervention: IV ketorolac 30 mg loading dose followed by IV ketorolac 15 mg every 6 hours (Group 2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IV ketorolac 60 mg loading dose followed by IV ketorolac 30 mg every 6 hours (Group 3)
Number of subjects: 62

Group type: COMPARATOR
Intervention: IV saline (placebo) followed by IV saline every 6 hours (Group 1)
Number of subjects: 62
Study: 3045341

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 mcg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Papaverine (7.5 mg) plus Phentolamine (0.25 mg)
Number of subjects: 12
Study: 29620927

Group type: EXPERIMENTAL
Intervention: Couple home visits conducted by lay health workers including health education, couple relationship and communication skills, and offers of couple HIV testing and counseling (CHTC) services.
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 127
Study: 26124656

Group type: EXPERIMENTAL
Intervention: Quadriceps isokinetic endurance test at 90° per second
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quadriceps isokinetic endurance test at 180° per second
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dyspnea and leg fatigue scores at both angular velocities
Number of subjects: 14
Study: 23219086

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 246
Study: 21552726

Group type: EXPERIMENTAL
Intervention: Direct and indirect intervention (Therapy Group - TG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Indirect intervention only (Orientation Group - OG)
Number of subjects: 11
Study: 18499632

Group type: EXPERIMENTAL
Intervention: 100 microg clonidine with 0.375% bupivacaine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 100 microg clonidine IM
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 99
Study: 16542657

Group type: COMPARATOR
Intervention: 125 mL intravenous fluid per hour
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 250 mL intravenous fluid per hour
Number of subjects: 300
Study: 12975159

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: ALA-ME-PDT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 10352088

Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 20 mg/day for 7 days (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 40 mg/day for 7 days (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups continued treatment with omeprazole (40 mg/day days 8-14 and 20 mg/day days 15-28)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Side effects recorded in group A
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Side effects recorded in group B
Number of subjects: 120
Study: 8686945

Group type: EXPERIMENTAL
Intervention: aprotinin (6.0 million KIU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 1858988

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with 1:400,000 epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:400,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (vasoconstrictor alone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 100
Study: 6685039

Group type: EXPERIMENTAL
Intervention: Optimal Loads (OL) for the legs: 5.04 Joule x Rev-1 x kg B.W.-1 for women and 5.13 Joule x Rev-1 x kg B.W.-1 for men.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Optimal Loads (OL) for the arms: 2.82 Joule x Rev-1 x kg B.W.-1 for women and 3.52 Joule x Rev-1 x kg B.W.-1 for men.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance loads ranged from 2.43 to 5.39 Joule per pedal revolution per kg body weight for legs and from 1.96 to 3.92 for arms.
Number of subjects: 35
Study: 29807102

Group type: EXPERIMENTAL
Intervention: Subetta add-on therapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 27581472

Group type: EXPERIMENTAL
Intervention: High energy intake at lunch (LM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: High energy intake at dinner (DM)
Number of subjects: 80
Study: 25503168

Group type: EXPERIMENTAL
Intervention: 10 mg or 20 mg of melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22424024

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10995

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10995
Study: 20001186

Group type: EXPERIMENTAL
Intervention: Intuitive-eating program
Number of subjects: 61
Study: 18215534

Group type: EXPERIMENTAL
Intervention: Mobile phone conversation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile phone use
Number of subjects: 60

Group type: COMPARATOR
Intervention: i-pod use
Number of subjects: 60

Group type: COMPARATOR
Intervention: No mobile device
Number of subjects: 60
Study: 16404981

Group type: EXPERIMENTAL
Intervention: Acilact
Number of subjects: 0

Group type: COMPARATOR
Intervention: IRS 19 vaccine
Number of subjects: 0
Study: 12702496

Group type: EXPERIMENTAL
Intervention: Enteral glutamine (0.8 mmol.kg body wt(‐1)x h(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isonitrogenous amino acids
Number of subjects: 0
Study: 10551433

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa receptor antagonists (parenteral formulations)
Number of subjects: 1000
Study: 8607684

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (20,000 kIU/kg [2.8 mg/kg])
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 25
Study: 1934206

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg.kg‐1 (ED95)
Number of subjects: 46

Group type: COMPARATOR
Intervention: d-tubocurarine 0.3 mg.kg‐1 (ED90)
Number of subjects: 46
Study: 7072708

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IPF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6705664

Group type: EXPERIMENTAL
Intervention: DKNA
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: DKNB
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: DKNC
Number of subjects: 219
Study: 29167074

Group type: EXPERIMENTAL
Intervention: Thermomechanical stimulation with the Buzzy device
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study: 28116299

Group type: EXPERIMENTAL
Intervention: Houpt overall behavior scale
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: OSUBRS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Venham Behavior Rating Scale
Number of subjects: 27
Study: 24641585

Group type: EXPERIMENTAL
Intervention: 20-week dietary intervention combined with physical exercise for weight loss
Number of subjects: 303

Group type: COMPARATOR
Intervention: Information-only arm (simple informative counselling)
Number of subjects: 303
Study: 22736737

Group type: EXPERIMENTAL
Intervention: Targeted self-care teaching intervention using principles of cognitive training
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 20589733

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-treated dyslipidemic T2D patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-dyslipidemic T2D patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 15
Study: 18330955

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Group 2)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (Group 3)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Untreated control group (Group 1)
Number of subjects: 76
Study: 15511602

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen preparation composed of 17-beta estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12050503

Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and oxygen)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 110
Study: 10480626

Group type: EXPERIMENTAL
Intervention: UCP3 splice mutation (homozygous)
Number of subjects: 942
Study: 8696019

Group type: EXPERIMENTAL
Intervention: Geliperm dressing applied to one eye
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard eye care applied to the other eye (control)
Number of subjects: 6
Study: 1761453

Group type: EXPERIMENTAL
Intervention: Cefprozil, 500 mg once a day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefaclor, 250 mg three times a day
Number of subjects: 102
Study: 6282790

Group type: EXPERIMENTAL
Intervention: Thoracic irradiation (TI) alone (4500‐6000 rad in 3‐6 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TI (3000 rad in 2 weeks) plus cyclophosphamide, doxorubicin, vincristine (CAV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TI + CAV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) plus high dose CAV, methotrexate and leucovorin
Number of subjects: 120
Study: 30288853

Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG) in group A
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG) in group B
Number of subjects: 150
Study: 28489320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin (COX inhibition)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spontaneous rewarming
Number of subjects: 24
Study: 26925896

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23698546

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 22179160

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 35
Study: 19479782

Group type: EXPERIMENTAL
Intervention: Discharge software
Number of subjects: 631

Group type: COMPARATOR
Intervention: Usual care, handwritten discharge
Number of subjects: 631
Study: 16835147

Group type: EXPERIMENTAL
Intervention: Menstrual pad technology A
Number of subjects: 10

Group type: COMPARATOR
Intervention: Menstrual pad technology B
Number of subjects: 10